News | News By Subject | News by Disease News By Date | Search News

Hunter's Syndrome News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
REGENXBIO's Gene Therapy for Hunter Syndrome Nabs FDA's 'Rare Pediatric Disease' Status     8/2/2016
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Shire Pharmaceuticals (SHPGY) Announces Approval of ELAPRASE(R) (idursulfase) in Brazil First and Only Treatment for Hunter Syndrome Now Approved in 40 Countries Worldwide     5/27/2008
Shire Pharmaceuticals Group plc (SHPGY)'s ELAPRASE(TM) (Idursulfase) Approved By The FDA For Hunter Syndrome     7/24/2006
Shire Pharmaceuticals Group plc (SHPGY) Provides Update On U.S. Marketing Application Of ELAPRASE(TM); FDA Delays Decision     5/17/2006
Transkaryotic Therapies, Inc. (TKTX) Reports Positive Top-Line Results Of Hunter Syndrome Pivotal Trial; Drug Data Dispel Acquisition Doubts For UK's Shire Pharmaceuticals (SHPGY)     6/20/2005
Transkaryotic Therapies, Inc. (TKT) (TKTX) Receives Fast Track Designation For Iduronate-2-Sulfatase For Hunter Syndrome     7/16/2004

News from Around the Web

Press Releases
Sangamo (SGMO) Presents New Data From In Vivo Protein Replacement Platform Programs For MPS I And MPS II At The 12th Annual WORLDSymposium Meeting     3/2/2016
Green Cross Gains Market Approval With the World's 2nd Orphan Drug for Hunter Syndrome in South Korea     1/27/2012
Shire Pharmaceuticals Group plc (SHPGY)'s ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome     2/13/2008
Shire Pharmaceuticals Group plc (SHPGY)'s ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome     10/5/2007
Shire Pharmaceuticals Group plc (SHPGY)'s ELAPRASE(TM) (idursulfase) Approved by Health Canada for Treatment of Hunter Syndrome     6/14/2007
Shire Pharmaceuticals Group plc (SHPGY) Release: ELAPRASE(R) For The Treatment Of Hunter Syndrome Approved By The European Commission     1/11/2007
Shire Pharmaceuticals Group plc (SHPGY) Files Idursulfase With EMEA For Treatment Of Hunter Syndrome     12/1/2005
Shire Pharmaceuticals Group plc (SHPGY) Files Elaprase(TM) (Idursulfase) With The FDA For The Treatment Of Hunter Syndrome     11/28/2005
Shire Pharmaceuticals Group plc (SHPGY) Presents Positive Results Of Hunter Syndrome Pivotal Clinical Trial At The American Society of Human Genetics Annual Meeting     10/28/2005
Transkaryotic Therapies, Inc. (TKTX) Release: New Website Offers Comprehensive Information On Hunter Syndrome     3/29/2005
Transkaryotic Therapies, Inc. (TKT) (TKTX) Research Findings On Intrathecal Delivery Of I2S Presented At ASHG     10/29/2004
Transkaryotic Therapies, Inc. (TKT)'s (TKTX) I2S For Hunter Syndrome Receives Office Of Orphan Products Grant     9/29/2004
Transkaryotic Therapies, Inc. (TKT) (TKTX) To Present Research On Intrathecal Delivery Of I2S For Hunter Syndrome At ASHG     9/20/2004
Transkaryotic Therapies, Inc. (TKT) (TKTX) Completes Patient Enrollment In Pivotal Hunter Syndrome Clinical Trial     3/5/2004
Transkaryotic Therapies, Inc. (TKT) (TKTX) To Complete Enrollment In Pivotal Hunter Syndrome Trial In Early March     2/23/2004

//-->